{"url_path":"/sec/mlys/8-k/2026-06-03/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1933414/0001628280-26-040225-index.html","accession_number":"0001628280-26-040225","cik":"0001933414","ticker":"MLYS","issuer_name":"Mineralys Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1933414/0001628280-26-040225-index.html","primary_entity_key":"0001933414","primary_entity_name":"Mineralys Therapeutics, Inc."},"word_count":118,"has_tables":true,"body_markdown":"Item 9.01   Financial Statements and Exhibits.\n\n(d)   Exhibits.\n\nExhibit No.Description\n\n1.1\n[Underwriting Agreement, dated June](exhibit11-8xk.htm)[3](exhibit11-8xk.htm)[, 2026, by and among Mineralys Therapeutics, Inc. and BofA Securities, Inc., Goldman Sachs & Co. LLC and Evercore Group L.L.C.](exhibit11-8xk.htm)\n\n5.1\n[Opinion of Latham & Watkins LLP](exhibit51-8k.htm)\n\n23.1\n[Consent of Latham & Watkins LLP (included in Exhibit 5.1)](exhibit51-8k.htm)\n\n99.1\n[Press Release dated June](exhibit991-underwriteragre.htm)[3](exhibit991-underwriteragre.htm)[, 2026](exhibit991-underwriteragre.htm)\n\n104Cover Page Interactive Data File (embedded within the Inline XBRL document)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nMINERALYS THERAPEUTICS, INC.\n\nDate: June 3, 2026\nBy:/s/ Adam Levy\n\nName:Adam Levy\n\nTitle:Chief Financial Officer and Secretary"}